SCHOLAR ROCK HOLDING CORPORATION Interest Expense Nonoperating
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Interest Expense Nonoperating of $4.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION interest expense nonoperating for the quarter ending 2026-06-30 was $4.52M, a 274.63% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION interest expense nonoperating for the quarter ending 2026-03-31 was $2.30M, a 26.62% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION interest expense nonoperating for the quarter ending 2025-12-31 was $2.53M, a 53.95% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION interest expense nonoperating for the quarter ending 2025-09-30 was $1.33M, a 23.51% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION interest expense nonoperating for fiscal 2025 was $6.89M, a 0.82% increase from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION interest expense nonoperating for fiscal 2024 was $6.84M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.52M 10-Q · filed 2026-08-06 | $6.82M 10-Q · filed 2026-08-06 | $9.35M derived: sum of 3 quarters · filed 2026-08-06 | $10.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.30M 10-Q · filed 2026-05-07 | $4.84M derived: sum of 2 quarters · filed 2026-05-07 | $6.17M derived: sum of 3 quarters · filed 2026-05-07 | $7.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.87M derived: sum of 2 quarters · filed 2026-03-03 | $5.07M derived: sum of 3 quarters · filed 2026-08-06 | $6.89M 10-K · filed 2026-03-03 |
| 2025-09-30 | $1.33M 10-Q · filed 2025-11-14 | $2.54M derived: sum of 2 quarters · filed 2026-08-06 | $4.36M 10-Q · filed 2025-11-14 | $6.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.21M 10-Q · filed 2026-08-06 | $3.02M 10-Q · filed 2026-08-06 | $4.67M derived: sum of 3 quarters · filed 2026-08-06 | $6.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.82M 10-Q · filed 2026-05-07 | $3.46M derived: sum of 2 quarters · filed 2026-05-07 | $5.21M derived: sum of 3 quarters · filed 2026-05-07 | $6.92M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.39M derived: sum of 2 quarters · filed 2026-03-03 | $5.11M derived: sum of 3 quarters · filed 2026-03-03 | $6.84M 10-K · filed 2026-03-03 |
| 2024-09-30 | $1.74M 10-Q · filed 2025-11-14 | $3.46M derived: sum of 2 quarters · filed 2025-11-14 | $5.19M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $1.72M 10-Q · filed 2025-08-06 | $3.45M 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |